Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi

In the setting of follicular lymphoma (FL), frontline therapy with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) has represented for many years the standard of care for patients with symptomatic advanced disease. More recently, the combination of bendamustine plus rituximab (R-B)...

Descripción completa

Detalles Bibliográficos
Autores principales: Margiotta-Casaluci, Gloria, Bigliardi, Sara, Cocito, Federica, Meli, Erika, Petrucci, Luigi, Nicolosi, Maura, Annibali, Ombretta, Boccomini, Carola, Bozzoli, Valentina, Castellino, Alessia, Cattina, Federica, Cenfra, Natalia, Ciavarella, Sabino, Kovalchuk, Sofya, Rotondo, Francesco, Fama, Angelo, Olivieri, Jacopo, Zaja, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036382/
https://www.ncbi.nlm.nih.gov/pubmed/36969038
http://dx.doi.org/10.3389/fonc.2023.1120967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036382/
https://www.ncbi.nlm.nih.gov/pubmed/36969038
http://dx.doi.org/10.3389/fonc.2023.1120967

Ejemplares similares